ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
A Nanomodulator Enhances Radiotherapy-Induced In Situ Cancer Vaccine by Promoting Antigen-Presenting of Tumor-Associated Macrophage.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The central role of radiotherapy in remodeling the tumor immune microenvironment: mechanisms and therapeutic implications.Frontiers in cell and developmental biology · 2026Review
- Tumor-associated macrophages: potential therapeutic strategies and future prospects in radioresistance of cancer.Frontiers in immunology · 2026Review
- Tumor-associated macrophages in cancer: from mechanisms to application.Molecular biomedicine · 2025Review
- A Nanomodulator Enhances Radiotherapy-Induced In Situ Cancer Vaccine by Promoting Antigen-Presenting of Tumor-Associated Macrophage.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Radiotherapy (RT) can induce an in situ vaccine effect by promoting the generation of tumor neoantigens, yet this effect is insufficient to elicit robust antitumor immune responses. Although the abundant tumor-associated macrophages (TAMs) in tumor tissue, as members of antigen-presenting cells, have been shown to capture antigens efficiently, the proteomic analysis, that TAMs is demonstrated exhibit up-regulated cysteine protease in lysosomes that leads to tumor antigen degradation. Inhibiting cysteine protease activity can promote the antigen-presenting of TAMs. Based on this, a nanomodulator (Ft-E64/Hf@Lipo) is developed, combining radiosensitizer hafnium (Hf) and the cysteine protease inhibitor E64, which cooperatively reinvigorated the antigen presentation of TAMs. Ft-E64/Hf@Lipo sensitized RT generated abundant tumor neoantigens, and then E64/antigens, along with the apoptotic tumor cells, trafficked to TAMs via efferocytosis. The reprogrammed TAMs with attenuated lysosomal function effectively presented tumor antigens and activated CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.